Treatment of cancer
AssigneeWakunaga Seiyaku Kabushiki Kaisha
InventorsHarunobu Amagase, Masato Arakawa, Ken Hashimoto
Life of this patent
Estimating the term…
Abstract
Antitumor effect of antitumor agents or treatments is favorably controlled by a growth factor. The growth factor enhances antitumor actions of antitumor agents or treatments including those against which tumor or cancer has acquired resistant, or reduces side effects due to the antitumor agents or treatments. The most typical growth factors include human epidermal growth factor. A lot of tumors or cancers including human ones has been tested and a lot of growth factors has been tested, and the favorable control has been determined.
Claims62
An antitumor composition, comprising (a) a compound having antitumor action which is at least one compound selected from the group consisting of alkylating agents, antimetabolites, antibiotics and platinum complexes, and (b) a growth factor which is at least one compound selected from the group consisting of compounds of the epidermal growth factor family and compounds of the platelet-derived growth factor family;
- wherein said alkylating agents are selected from the group consisting of chloromethyne analogues, nitrogen mustard analogues, ethyleneimino analogues, alkylsulfonic acid analogues, nitrosourea analogues, and epoxide analogues;
- wherein said antimetabolites are selected from the group consisting of folic acid antagonist analogues, purine antagonist analogues, pyridine antagonist analogues, Tegafur, and uracil formulated into Tegafur;
- wherein said antibiotics are selected from the group consisting of actinomycin analogues, azaserine, DON, sarkomycin, carzinophilin, mitomycin analogues, chromomycin A.sub.3 analogues, bleomycin, peplomycin, daunorubicin, adriamycin, and aclarubicin;
- and
- wherein said platinum complexes are selected from the group consisting of cisplatin, carboplatin, ipuloplatin.
A method of controlling antitumor action in chemotherapy, radiation therapy or thermotherapy in which antitumor treatment is practiced, which method comprises administering to a patient under said treatment, during or after the application to the patient of an antitumor chemical which is at least one compound selected from the group consisting of alkylating agents, antimetabolites, antibiotics and platinum complexes, irradiation or heat, an antitumor controlling composition, comprising a growth factor which is at least one compound selected from the group consisting of compounds of the epidermal growth factor family and compounds of the platelet-derived growth factor family;
- wherein said alkylating agents are selected from the group consisting of chloromethyne analogues, nitrogen mustard analogues, ethyleneimino analogues, alkylsulfonic acid analogues, nitrosourea analogues, and epoxide analogues;
- wherein said antimetabolites are selected from the group consisting of folic acid antagonist analogues, purine antagonist analogues, pyridine antagonist analogues, Tegafur, and uracil formulated into Tegafur;
- wherein said antibiotics are selected from the group consisting of actinomycin analogues, azaserine, DON, sarkomycin, carzinophilin, mitomycin analogues, chromomycin A.sub.3 analogues, bleomycin, peplomycin, daunorubicin, adriamycin, and aclarubicin;
- and
- wherein said platinum complexes are selected from the group consisting of cisplatin, carboplatin, ipuloplatin.
Dependencies are inferred from the claim text.